InnFocus Inc.’s MicroShunt glaucoma drainage implant is designed to reduce intraocular pressure in glaucoma patients. President and CEO Russell Trenary explained that the implant is made from a revolutionary and highly biocompatible material that is ultra-stable and does not degrade. In the past year, InnFocus has been conducting the first randomized controlled study against trabeculectomy, the gold standard in managing later-stage glaucoma patients.
Russ Trenary is President & CEO for InnFocus, Inc., an early stage company pioneering a microsurgical solution for glaucoma. He has led, or been a named officer, for medical device companies, for over 20 years.